SubioMed
Private Company
Total funding raised: $3M
Overview
SubioMed is a private, pre-revenue medical device innovator developing a novel biomechanics platform. Its core technology, Suspension Biomechanics™, is designed to absorb, translate, and return energy during gait to mitigate wear-and-tear on joints, with initial applications in foot and ankle health. The company aims to address the growing burden of lower extremity injuries and degenerative conditions, such as osteoarthritis, driven by aging, obesity, and inactivity. SubioMed is in the early commercial strategy phase, seeking to translate its patented technology into medical and consumer products.
Technology Platform
Patented Suspension Biomechanics™ technology designed to dynamically manage Ground Reaction Forces (GRF) during gait. It operates in three phases: Deceleration & Energy Absorption (dampens impact), Energy Translation & Suspension (captures kinetic energy, minimizes transfer to joints), and Energy Return (provides propulsive assist). It also includes Precision Motion Control for medial/lateral stability.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
SubioMed faces competition from established orthopedic device companies (e.g., Stryker, Zimmer Biomet for joints), bracing and support companies (e.g., DJO, Ossur), and footwear/orthotic innovators (e.g., Hoka, APOS Therapy). Its differentiation hinges on proving its unique energy management and return system provides superior clinical and functional outcomes compared to existing passive support or cushioning technologies.